Novo Nordisk aims to cement its dominance in the obesity market, says GlobalData

Novo Nordisk’s recent announcement of positive topline data from its Phase IIIa study STEP 4, investigating the use of semaglutide to treat obesity, will enable it to remain a leader in the obesity space, according to GlobalData, a leading data and analytics company.

In early May, Novo Nordisk announced positive topline data from its Phase IIIa study STEP 4, investigating the use of semaglutide in achieving sustained weight reduction for those suffering from obesity. This randomized, double-blind, multicenter, placebo-controlled, withdrawal trial explored the use of subcutaneously administered semaglutide in comparison to a placebo. This is significant for the global obesity market, where Novo Nordisk’s Saxenda (liraglutide) currently occupies a 55% market share.

Akash Patel Healthcare Analyst at GlobalData, commented: “The STEP 4 trial results demonstrated that semaglutide is highly efficacious in the treatment of obesity and has a safe and well-tolerated profile. In addition to demonstrating high efficacy for weight loss, semaglutide was shown to maintain sustained weight loss partially due to its efficacy but also due an increased rate of compliance from its once-weekly administration.”

Earlier this year, Ozempic (semaglutide) received a label update towards reducing major adverse cardiovascular event (MACE) risks in patients with type 2 diabetes (T2D) and known heart disease. The drug has a strong reputation in the T2D space, as expressed by key opinion leaders interviewed by GlobalData. Its growing name recognition, combined with positive experience physicians have described from prescribing the drug, will be a key driver for rapid uptake of semaglutide, if approved for obesity.

Patel adds: “It is important to note that 57% of diagnosed T2D patients in the US suffer from obesity, which will likely lead physicians to increasingly favor prescribing semaglutide for treatment.”

More Media